Free Trial

Senti Biosciences Q3 2023 Earnings Report

Senti Biosciences logo
$4.42 +0.16 (+3.76%)
As of 01/30/2025 04:00 PM Eastern

Senti Biosciences EPS Results

Actual EPS
-$2.50
Consensus EPS
-$4.80
Beat/Miss
Beat by +$2.30
One Year Ago EPS
N/A

Senti Biosciences Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
$0.94 million
Beat/Miss
Missed by -$600.00 thousand
YoY Revenue Growth
N/A

Senti Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A

Senti Biosciences Earnings Headlines

Senti Bio Announces Additional $11.5 Million of Financing
Do this Before Elon’s Reveal on April 23rd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Senti Bio announces first patient dosed in clinical trial of SN301A
See More Senti Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Senti Biosciences Profile

More Earnings Resources from MarketBeat